An Opportunity to Save Lives

ih-gradient-300px



 

 

Why It Matters

ih-gradient-300px

Infinant Health is offering a groundbreaking investment opportunity in a pharmaceutical product poised to revolutionize NICU care.

Infinant Health's innovative solutions has the potential to prevent necrotizing enterocolitis (NEC) and save the lives of vulnerable preterm infants, while significantly enhancing NICU outcomes.

What is NEC?

ih-gradient-300px

Necrotizing Enterocolitis (NEC) claims more than one infant per day in the US, with an estimated 500 deaths per year.

Microsite photo NICU baby (2400 x 3529 px)

NEC is the deadliest threat to preterm infants

ih-gradient-90px

Necrotizing enterocolitis, or NEC, is the death of intestinal tissue primarily seen in preterm infants. It occurs when the intestinal wall lining becomes inflamed and dies. Although the cause for this disorder is unknown, it is thought that a decrease in blood flow to the bowel keeps the bowel from producing mucus that protects the gastrointestinal tract. Certain types of bacteria in the intestine may also be a cause.

NEC is the deadliest threat to preterm infants, with over 500 deaths a year in the United States, that is more than one infant death per day.

Today the only Treatment for NEC is major surgery

ih-gradient-90px

Unfortunately, NEC is spontaneous and unpredictable, and major surgery is the only available treatment today. The lower the birth weight, and the younger the gestational age of the baby, the higher the risk of NEC. Younger preemies are at risk of higher mortality due to NEC.

Strong scientific and clinical evidence suggests that B. infantis is associated with a significant reduction in the incidence of NEC and  NEC-related mortality in very low birth weight infants.  The microbiomes of preterm infants given B. infantis also contain lower levels of antibiotic resistance organisms and show biomarkers for reduced gut inflammation. (See research below)

0001-6526154768479471928
Image_233_GettyImages-73773084

The high cost of NEC for patients & insurance companies

ih-gradient-90px

NEC patients often require not only medical care but also surgical interventions, which drive up healthcare costs and extend hospital stays.

The expenses associated with NEC are substantial, accounting for nearly 20 percent of the total cost of newborn care in the United States, which translates to upwards of $5 billion annually.*

NICU Costs in the U.S.

ih-gradient-300px

NICU cost at discharge graph
NICU costs 6-36 months

*Sources::
1. Bisquera JA, Cooper TR, Berseth CL. Impact of necrotizing enterocolitis on length of stay and hospital charges in very low birth weight infants. Pediatrics. 2002 Mar;109(3):423-8. doi: 10.1542/peds.109.3.423. PMID: 11875136.
2. Gephart SM, McGrath JM, Effken JA, Halpern MD. Necrotizing enterocolitis risk: state of the science. Adv Neonatal Care. 2012 Apr;12(2):77-87; quiz 88-9. doi: 10.1097/ANC.0b013e31824cee94. PMID: 22469959; PMCID: PMC3357630.

The Solution

ih-gradient-300px

Infinant Health's B. infantis INF108 is the next-generation product developed from the learnings on EVC001. 

Tobias-1

Tobias, J. et al. Bifidobacterium longum subsp. infantis EVC001 Administration Is Associated with a Significant Reduction in the Incidence of Necrotizing Enterocolitis in Very Low Birth Weight Infants. J Pediatrics 244, 64-71.e2 (2022).

Sohn

Kristin Sohn, Victoria Palacios, Reese Clark et al. Bifidobacterium longum subsp infantis (EVC001) is Associated with Reduced Incidence of Necrotizing Enterocolitis Stage >2 and Bloody Stools in Premature Babies, 01 August 2024, PREPRINT (Version 1) available at Research Square

Disclaimer: INF108 is a drug candidate based on the learnings from EVC001. EVC001 is not approved or intended to prevent, treat, cure, or mitigate any disease. EVC001 is intended for healthy, full-term infants only.

Contact Us

ih-gradient-300px

Call us at (844) 463-8486 for customer service, support, and to learn more about our products.